Thyroid Eye Disease Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutic

DelveInsight’s “Thyroid Eye Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Thyroid Eye Disease, historical and forecasted epidemiology as well as the Thyroid Eye Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Thyroid Eye Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Thyroid Eye Disease Market Forecast

Some of the key facts of the Thyroid Eye Disease Market Report: 

• The Thyroid Eye Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In Europe, the overall pooled prevalence of TED was 38% (CI: 0.31 to 0.46), in Asia it was 44% (CI: 0.32 to 0.56), in North America it was 27% (CI: 0.06 to 0.56), in Oceania it was 58% (CI: 0.55 to 0.61), and in Southeast Asia it was 35% (CI: 0.24 to 0.47)
• Karla et al. (2020) found that among thyroid eye illness patients worldwide, the prevalence of hypothyroidism was 10.36%, euthyroidism was 7.9%, and hyperthyroidism was 86.2%
• Key Thyroid Eye Disease Companies: Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron Pharmaceuticals, ValenzaBio, ACELYRIN Inc., Horizon Therapeutics USA, Inc., Neothetics, Inc, Sling Therapeutics, Inc., Novartis, and others
• Key Thyroid Eye Disease Therapies: Batoclimab (IMVT 1401), COSENTYX (secukinumab), VRDN-001, Linsitinib, Aflibercept, VB421, RVT-140, lonigutamab, Teprotumumab, LIPO-102, Linsitinib, CFZ533, and others
• The Thyroid Eye Disease epidemiology based on gender analyzed that the incidence of Thyroid Eye Disease is 16 per 100,000 females and 2.9 per 100,000 males with an approximate prevalence of 0.25% with no significant ethnic predisposition
• The Thyroid Eye Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Thyroid Eye Disease pipeline products will significantly revolutionize the Thyroid Eye Disease market dynamics.

Thyroid Eye Disease Overview

A complex orbital inflammatory condition that can be sight-threatening, incapacitating, and disfiguring is known as thyroid eye disease (TED). In honour of Robert J. Graves, an Irish doctor who first identified thyrotoxicosis in a woman presenting with goitre, rapid heartbeat, and exophthalmos, TED is also known as Graves’ ophthalmopathy.

Get a Free sample for the Thyroid Eye Disease Market Report 

https://www.delveinsight.com/report-store/thyroid-eye-disease-market

Thyroid Eye Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Thyroid Eye Disease Epidemiology Segmentation:

The Thyroid Eye Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Thyroid Eye Disease
• Prevalent Cases of Thyroid Eye Disease by severity
• Gender-specific Prevalence of Thyroid Eye Disease
• Diagnosed Cases of Episodic and Chronic Thyroid Eye Disease

Download the report to understand which factors are driving Thyroid Eye Disease epidemiology trends @ Thyroid Eye Disease Epidemiology Forecast

Thyroid Eye Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Thyroid Eye Disease market or expected to get launched during the study period. The analysis covers Thyroid Eye Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Thyroid Eye Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Thyroid Eye Disease Therapies and Key Companies

• Batoclimab (IMVT 1401): Immunovant Sciences
• COSENTYX (secukinumab): Novartis
• VRDN-001: Viridian Therapeutics
• Linsitinib: Sling Therapeutics
• Aflibercept: Regeneron Pharmaceuticals
• VB421: ValenzaBio
• Secukinumab: Novartis
• RVT-1401: Immunovant Sciences GmbH
• lonigutamab: ACELYRIN Inc.
• Teprotumumab: Horizon Therapeutics USA, Inc.
• LIPO-102: Neothetics, Inc
• Linsitinib: Sling Therapeutics, Inc.
• CFZ533: Novartis

Discover more about therapies set to grab major Thyroid Eye Disease market share @ Thyroid Eye Disease Treatment Market

Scope of the Thyroid Eye Disease Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Thyroid Eye Disease Companies: Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron Pharmaceuticals, ValenzaBio, ACELYRIN Inc., Horizon Therapeutics USA, Inc., Neothetics, Inc, Sling Therapeutics, Inc., Novartis, and others
• Key Thyroid Eye Disease Therapies: Batoclimab (IMVT 1401), COSENTYX (secukinumab), VRDN-001, Linsitinib, Aflibercept, VB421, RVT-140, lonigutamab, Teprotumumab, LIPO-102, Linsitinib, CFZ533, and others
• Thyroid Eye Disease Therapeutic Assessment: Thyroid Eye Disease current marketed and Thyroid Eye Disease emerging therapies
• Thyroid Eye Disease Market Dynamics: Thyroid Eye Disease market drivers and Thyroid Eye Disease market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Thyroid Eye Disease Unmet Needs, KOL’s views, Analyst’s views, Thyroid Eye Disease Market Access and Reimbursement 

To know more about Thyroid Eye Disease companies working in the treatment market, visit @ Thyroid Eye Disease Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Thyroid Eye Disease Market Report Introduction

2. Executive Summary for Thyroid Eye Disease

3. SWOT analysis of Thyroid Eye Disease

4. Thyroid Eye Disease Patient Share (%) Overview at a Glance

5. Thyroid Eye Disease Market Overview at a Glance

6. Thyroid Eye Disease Disease Background and Overview

7. Thyroid Eye Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Thyroid Eye Disease 

9. Thyroid Eye Disease Current Treatment and Medical Practices

10. Thyroid Eye Disease Unmet Needs

11. Thyroid Eye Disease Emerging Therapies

12. Thyroid Eye Disease Market Outlook

13. Country-Wise Thyroid Eye Disease Market Analysis (2019–2032)

14. Thyroid Eye Disease Market Access and Reimbursement of Therapies

15. Thyroid Eye Disease Market Drivers

16. Thyroid Eye Disease Market Barriers

17.  Thyroid Eye Disease Appendix

18. Thyroid Eye Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services